Official ERS Assembly 12 - Interstitial Lung Disease - Twitter account. Managed by the Assembly officers.
Joined September 2021
- Tweets173
- Following141
- Followers798
- Likes310
📩 Check your emails! You'll find the booking link for the Assembly social dinner at #ERSCongress and a summary of all ILD sessions not to miss.
#ILD #ERS2025 #ECM #Networking
channel.ersnet.org/channel-3…
Watch the last coffee talk episode. Cormac McCarthy and Nishant Gupta discuss how diffuse cystic lung diseases (DCLDs) differ from typical fibroinflammatory interstitial lung diseases.
ERS Assembly 12 - ILD retweeted
Presented at #ATS2025:
In the PREDMETH trial, first-line treatment of pulmonary sarcoidosis with methotrexate was noninferior to that with prednisone regarding the change at 24 weeks in the percentage of the predicted forced vital capacity. Full trial results: nej.md/4kdaf0o
Editorial: Methotrexate as Initial Therapy for Symptomatic Pulmonary Sarcoidosis? nej.md/4mhaHfW
@atscommunity
ALT The unadjusted mean change in the percentage of the predicted forced vital capacity (FVC) in the prednisone and methotrexate groups between baseline and weeks 4, 16, and 24.
ERS Assembly 12 - ILD retweeted
سعدت بالمشاركة🇸🇦 في كتابة هذه الورقة مع نخبة من الباحثين المتميزين من هولندا، ألمانيا، بريطانيا، وإيطاليا، والمنشور في ERJ Open Research.
@KarenMoor2 @Istamina
Our latest article has been published in ERJ Open Research! It was a pleasure to work with Dr Laura, Karen, Prof. Marlies Wijsenbeek, and Michael Kreuter.
pmc.ncbi.nlm.nih.gov/article…
🚨 Only 2 weeks left to apply for the ECM Mentoring Programme! 🚨
If you applied before Jan 15, please resubmit your application to ensure it's received. Don't miss this opportunity—apply now!
🌟 Excited to grow your career? The ERS Assembly 12 Mentoring Programme is launching!
💡 Gain insights, set goals, and connect with mentors & peers through 5 interactive sessions (virtual + onsite at #ERS2025).
⏳ Apply by Jan 31, 2025: forms.office.com/e/kCNNRetdD…
#Mentorship #ERS
ERS Assembly 12 - ILD retweeted
Cannot wait to see the data from the FIBRONEER Phase III trial of nerandomilast in IPF! This is a very exciting development on the back of all the earlier Phase II study results... And a very timely announcement in the middle of PF awareness month!
#NEWS: We’re excited to announce that our Phase III trial in people living with idiopathic pulmonary fibrosis (IPF) met its primary endpoint.
Learn more here: bit.ly/47JWDoB
Thanks for a fantastic ERS congress. We've had so many inspiring ILD sessions and were very happy to meet old friends and new (young) colleagues! Safe trip back home and see you in Amsterdam next year. #ERSCongress2024 #Assembly12 @michael_kreuter @Katerin16265046
@KarenMoor2
ERS Assembly 12 - ILD retweeted
Hard core ILD group left at the very end of #ERSCongress2024 @PilarRiveraOrt1
Do not miss it! We all encounter these challenging questions in our daily practice #ERSCongress2024
Great pro-con debate between @ILDIPFDoc_NI and George Margaritopoulos answering the question: Should advanced age and comorbidities prevent you from initiating antifibrotic therapy? If you're not present, watch it on your way back home! #ERSCongress2024 @Katerin16265046
ERS Assembly 12 - ILD retweeted
I hope you enjoyed meeting us! Please fill out the form above and keep your competencies list up to date on Myers' profile.
ERS Assembly 12 - ILD retweeted
Interesting joint lecture format with pulmonologist @michael_kreuter and rheumatologist @hoffmann_vold discussing #ILD and the value of multidisciplinary teams 🫁 #ERSCongress – at Vienna, Austria
What a great Tuesday! 4 amazing ILD symposia/hot topic sessions on one day, followed by our Assembly meeting and networking event💪 So nice to meet many ILD colleagues in person in beautiful Vienna #ERSCongress2024 @EuroRespSoc
Very busy poster sessions ongoing, PS28-29-30! Welcome to join the discussions #ERSCongress
From omics to clinical care in ILD, now in Room A3. Don't miss it! #ERSCongress2024
Breaking news in ILD of known origin. Join us now in room Strauss 1! #ERSCongress
Looking forward to meeting you at this session on novel management strategies in pulmonary fibrosis Room A1 #ERSCongress
Even the overflow area is full for the ILD state if the art session #ERScongress
Take your sandwich to the interesting ILD poster sessions #ERScongress
Full house for the oral presentation session advances in clinical practice for rare ILDs in Room A3 #ERScongress @PilarRiveraOrt1
